Literature DB >> 12368370

Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach.

Vijay Dhawan1, Yilong Ma, Vandhana Pillai, Phoebe Spetsieris, Thomas Chaly, Abdelfatihe Belakhlef, Claude Margouleff, David Eidelberg.   

Abstract

UNLABELLED: Striatal-to-occipital ratio (SOR) and influx constant K(i)(occ) are commonly used as analytic parameters in L-3,4-dihydroxy-6-(18)F-fluorophenylalanine (FDOPA) PET studies. Both have been shown to be useful in discriminating Parkinson's disease (PD) patients from healthy subjects. We evaluated the relative performance of SOR and influx constant (K(i)(occ)) in the clinical assessment of nigrostriatal dopaminergic function in PD.
METHODS: Twenty-one parkinsonian patients (Hoehn and Yahr scale I-IV; mean age +/- SD, 56 +/- 9.2 y) and 11 healthy subjects (mean age, 60 +/- 16 y) underwent 3-dimensional dynamic FDOPA scanning from 0 to 100 min. After spatial realignment, PET images at each frame were integrated by summing 4 central striatal slices, and time-activity curves (TACs) were generated after placing a standard set of elliptic regions of interest over striatal and occipital structures. SOR and K(i)(occ) values for each subject were then computed from TACs at different times using an input function from the occipital cortex.
RESULTS: Both SOR and K(i)(occ) showed significant bilateral decreases in striatal dopamine uptake in the PD group compared with the control group. SOR values estimated for 10-min frames between 65 and 95 min are statistically equivalent in group discrimination. In addition, SOR values in the caudate and putamen correlated strongly with K(i)(occ), especially toward the end of the scanning epoch. Both parameters correlated significantly and comparably with Unified Parkinson's Disease Rating Scale motor scores.
CONCLUSION: These results suggest that SOR determined from a single 10-min scan at 95 min is as accurate as K(i)(occ) in separating PD patients from healthy subjects and in predicting clinical measures of disease severity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368370

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET.

Authors:  I Lopes Alves; Sanne K Meles; Antoon Tm Willemsen; Rudi A Dierckx; Ana M Marques da Silva; Klaus L Leenders; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-19       Impact factor: 6.200

2.  Dopaminergic correlates of metabolic network activity in Parkinson's disease.

Authors:  Florian Holtbernd; Yilong Ma; Shichun Peng; Frank Schwartz; Lars Timmermann; Lutz Kracht; Gereon R Fink; Chris C Tang; David Eidelberg; Carsten Eggers
Journal:  Hum Brain Mapp       Date:  2015-06-03       Impact factor: 5.038

3.  Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.

Authors:  Rachel Saunders-Pullman; Johann Hagenah; Vijay Dhawan; Kaili Stanley; Gregory Pastores; Swati Sathe; Michele Tagliati; Kelly Condefer; Christina Palmese; Norbert Brüggemann; Christine Klein; Am Roe; Ruth Kornreich; Laurie Ozelius; Susan Bressman
Journal:  Mov Disord       Date:  2010-07-30       Impact factor: 10.338

4.  (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Authors:  Aaron F Struck; Lance T Hall; Joanna E Kusmirek; Catherine L Gallagher; John M Floberg; Christine J Jaskowiak; Scott B Perlman
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

5.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

6.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

7.  Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.

Authors:  R Hilker; A T Portman; J Voges; M J Staal; L Burghaus; T van Laar; A Koulousakis; R P Maguire; J Pruim; B M de Jong; K Herholz; V Sturm; W-D Heiss; K L Leenders
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

8.  Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes.

Authors:  Yilong Ma; Chengke Tang; Thomas Chaly; Paul Greene; Robert Breeze; Stanley Fahn; Curt Freed; Vijay Dhawan; David Eidelberg
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

9.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

10.  Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Authors:  M J Barrett; J Hagenah; V Dhawan; S Peng; K Stanley; D Raymond; A Deik; S J Gross; N Schreiber-Agus; A Mirelman; K Marder; L J Ozelius; D Eidelberg; S B Bressman; R Saunders-Pullman
Journal:  Parkinsonism Relat Disord       Date:  2012-10-10       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.